Tricuspid Regurgitation Clinical Trials

Find Tricuspid Regurgitation Clinical Trials Near You

3D Transthoracic Echocardiographic Evaluation on Tricuspid Regurgitation Progression and Clinical Outcomes in Patients With Cardiac Implantable Electronic Device

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this observational study is to learn about the development and worsening of tricuspid regurgitation (TR) in patients who have cardiac implantable electronic devices (CIEDs). The main objective is to compare left bundle branch area pacing (LBBaP) and leadless pacemakers against conventional pacemakers in terms of TR exacerbation. Participants with these devices will have their retrospective and prospective clinical data analyzed and will undergo 3D transthoracic echocardiography to identify the exact mechanical causes of TR.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:

• Aged 19 years or older.

• Patients who are at least one year post-implantation of one of the following Cardiac Implantable Electronic Devices (CIEDs):

⁃ A. Permanent Pacemaker (PPM) B. Implantable Cardioverter-Defibrillator (ICD) C. Leadless Pacemaker

• Patients who underwent the implantation procedure on or after January 2022.

• Voluntary informed consent provided by the patient or their legal representative for the review of medical records and study-related data throughout the entire study period.

Locations
Other Locations
Republic of Korea
Samsung Medical Center
RECRUITING
Seoul
Contact Information
Primary
Juwon Kim
abcd186a@naver.com
82+ 2-3410-3419
Time Frame
Start Date: 2026-01-22
Estimated Completion Date: 2028-01-31
Participants
Target number of participants: 1000
Treatments
A patient one year after receiving a cardiac implantable electronic device
Subjects aged 19 years or older who underwent de novo implantation of a leadless PPM or a cardiac implantable electronic device (PPM or ICD) at Samsung Medical Center between 2022 and 2025, and are at least one year post-implantation
Related Therapeutic Areas
Sponsors
Leads: Samsung Medical Center

This content was sourced from clinicaltrials.gov